One placebo-controlled trial «Arnold LM, Goldenberg DL, Stanford SB, ym. Gabapen...»1 tested the effect of gabapentin (versus placebo) on fibromyalgia. The average pain decreased by 0.95 points compared to control (about 25% difference).
Most common adverse effects were dizziness (RD 16%), sedation (20%), lightheadedness (10%), weight gain (6%).
The evidence was limited by high risk of bias and imprecision.
| Reference | Study type | Population | Intervention and comparison | Outcomes | Risk of bias |
|---|---|---|---|---|---|
| RCT=randomized controlled trial; SR=systematic review; MA=meta-analysis; NMA=network meta-analysis; FIQ=Fibromyalgia impact questionnaire | |||||
| «Arnold LM, Goldenberg DL, Stanford SB, ym. Gabapen...»1 | RCT | Adults with fibromyalgia | Gabapentin 1200-2400mg per day vs placebo | Average pain, quality of life (FIQ) | High |
| Reference | Comments |
|---|---|
| «Arnold LM, Goldenberg DL, Stanford SB, ym. Gabapen...»1 | Inclusion criteria: female and male, 18 years and over, FM patients meeting ACR criteria
for FM (1990), score ≥ 4 on BPI scale at screening and andomization. High risk of bias (about 20 % dropout rates). |
| Reference | Number of studies and number of patients | Follow-up time | Mean at follow up (sd) I | Mean at follow up (sd) C | Mean difference (95% CI) |
|---|---|---|---|---|---|
| Level of evidence: low The quality of evidence is downgraded due to study limitations and imprecision. I=intervention; C=comparison; CI=confidence interval |
|||||
| «Arnold LM, Goldenberg DL, Stanford SB, ym. Gabapen...»1 | 75/75 | 12 weeks | 3.8 (2.2) | 5.0 (2.6) | -0.95 (-1.68 to -0.23) |
| Reference | Number of studies and number of patients (I/C) | Follow-up time | Mean at follow up (sd) I | Mean at follow up (sd) C | Mean difference (95% CI) |
|---|---|---|---|---|---|
| Level of evidence: low The quality of evidence is downgraded due to study limitations and imprecision. I=intervention; C=comparison; CI=confidence interval |
|||||
| «Arnold LM, Goldenberg DL, Stanford SB, ym. Gabapen...»1 | 75/75 | 12 weeks | 26.2 (15.1) | 37.3 (18.1) | -8.4 (-13.0 to -3.3) |